Evidence map›Paper›PMID 37511111›Full record

ArticleInternational journal of molecular sciences2023

The Role of

Imrich Géci, Peter Bober, Eva Filová, Evžen Amler, Ján Sabo

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Imrich GéciDepartment of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Košice, Slovakia.ORCID 0000-0003-0059-9693
Peter BoberDepartment of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Košice, Slovakia.ORCID 0000-0002-6594-3689
Eva FilováInstitute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, 142 00 Prague, Czech Republic.ORCID 0000-0003-1028-605X
Evžen AmlerInstitute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, 142 00 Prague, Czech Republic.
Ján SaboDepartment of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Košice, Slovakia.
University of Pavol Jozef Šafárik · SKCzech Academy of Sciences · CZ

Funding

The Ministry of Education, Science, Research and Sport of the Slovak Republic ITMS: 313011AUB1
6 · The paper itself

Abstract

Breast cancer is the most prevalent cancer type in women worldwide. It proliferates rapidly and can metastasize into farther tissues at any stage due to the gradual invasiveness and motility of the tumor cells. These crucial properties are the outcome of the weakened intercellular adhesion, regulated by small guanosine triphosphatases (GTPases), which hydrolyze to the guanosine diphosphate (GDP)-bound conformation. We investigated the inactivating effect of

Indexed as

Breast NeoplasmsGTPase-Activating Proteinsrho GTP-Binding Proteinscdc42 GTP-Binding ProteinDoxorubicinFemaleHumansMCF-7 CellsProteomicsrac1 GTP-Binding ProteinrhoA GTP-Binding ProteinARHGAP1 protein, humancdc42 GTP-Binding ProteinDoxorubicinGTPase-Activating Proteinsrac1 GTP-Binding ProteinrhoA GTP-Binding Proteinrho GTP-Binding Proteinsbreast cancercell adhesiondoxorubicinmass spectrometrymetastasesproteomics

Identifiers

PMID37511111
PMCPMC10379778
OpenAlexW4384264188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.